Izvorni znanstveni članak
https://doi.org/10.3325/cmj.2023.64.354
Does switching from coated colchicine to compressed colchicine improves treatment response in patients with familial Mediterranean fever?
Nimet Öner
orcid.org/0000-0003-0403-151X
; Ankara Bilkent City Hospital, Ankara, Turkey
*
Elif Çelikel
; Ankara Bilkent City Hospital, Ankara, Turkey
Zahide Ekici Tekin
; Ankara Bilkent City Hospital, Ankara, Turkey
Vildan Güngörer
; Ankara Bilkent City Hospital, Ankara, Turkey
Tuba Kurt
; Ankara Bilkent City Hospital, Ankara, Turkey
Müge Sezer
; Ankara Bilkent City Hospital, Ankara, Turkey
Nilüfer Tekgöz
; Ankara Bilkent City Hospital, Ankara, Turkey
Cüneyt Karagöl
; Ankara Bilkent City Hospital, Ankara, Turkey
Serkan Coşkun
; Ankara Bilkent City Hospital, Ankara, Turkey
Melike Mehveş Kaplan
; Ankara Bilkent City Hospital, Ankara, Turkey
Merve Cansu Polat
; Ankara Bilkent City Hospital, Ankara, Turkey
Banu Çelikel Acar
; Ankara Bilkent City Hospital, Ankara, Turkey
* Dopisni autor.
Sažetak
Aim To evaluate the treatment response to compressed
colchicine tablets in familial Mediterranean fever (FMF) patients with resistance or intolerance to coated colchicine.
The secondary aim was to determine the demographic
and clinical characteristics of responders to compressed
colchicine.
Methods We retrospectively reviewed the medical records of 1574 pediatric patients with FMF treated at Ankara Bilkent City Hospital. Sixty-one patients did not respond
to coated colchicine and were switched to compressed
colchicine. In these patients, the number of attacks and
the International Severity Score for FMF (ISSF) during the 6
months before and 3, 6, 9, 12, and 24 months after switching from coated colchicine to compressed colchicine were
recorded.
Results Twelve of 61 patients (19.7%) who were switched
to compressed colchicine due to intolerance responded to treatment. Of the 49/61 patients (80.3%) who were
switched due to uncontrolled attacks and persistent subclinical inflammation, 25 responded to treatment. The frequency of attacks and ISSF decreased after switching. At
the end of the two-year follow-up, 42 patients responded
to compressed colchicine, and 19 patients received compressed colchicine plus interleukin-1-targeting drugs.
Conclusions Compressed colchicine was shown to be a
useful treatment option before initiating biological agents
in non-responders to coated colchicine, especially those
with side effects.
Ključne riječi
Hrčak ID:
331874
URI
Datum izdavanja:
30.9.2024.
Posjeta: 39 *